Capricor Therapeutics, Inc. is a biotech company that develops treatments for various diseases and disorders using cell and exosome-based therapies. Its lead candidate, CAP-1002, has completed phase III clinical trials for Duchenne muscular dystrophy and is in phase II trials for cytokine storm associated with SARS-CoV-2. The company is also developing other therapies, including a potential COVID-19 vaccine.